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Early discharge has increased the confusion associated with the problem of hyperbilirubinemia. As a result, concerns for newborns have arisen because of the difficulty in accurately predicting which infants may be at risk for bilirubin-induced brain damage; in addition, intensive follow-up clinic programs for monitoring plasma bilirubin levels in this neonatal population are not universally available. 2, 3 The demonstration that a synthetic heme analog could, by acting as a competitive inhibitor, strongly inhibit the activity of heme oxygenase (HO), the rate-limiting enzyme in heme catabolism, 4 and concurrently suppress naturally occurring or experimentally induced hyperbilirubinemia in animals and in humans 5, 6 has opened the way to a new therapeutic approach to the treatment of newborn jaundice. Tin-mesoporphyrin (SnMP) is a potent HO inhibitor developed to date 7 and has undergone extensive clinical study without serious side effects. The only side effect observed has been a transient, non-dose-dependent erythema that disappeared without sequelae in infants who received phototherapy (PT) after SnMP administration. 8 It was first reported in 1987 that the reduction of the two vinyl groups, to form ethyl groups, at the C2 and C4 positions of the porphyrin macrocycle to form SnMP, greatly enhanced the potency of the metalloporphyrin to inhibit HO activity and diminish bilirubin production, and thus could moderate naturally occurring and experimentally induced hyperbilirubinemia in the postnatal animal. The compound also decreased biliary bilirubin output whether the bile pigment was derived from the catabolism of endogenous or exogenous heme, simultaneously enhanced the output of unmetabolized heme in bile, whether the heme was derived from endogenous or exogenous sources. These results demonstrated that substitutions on the porphyrin macrocycle as well as the nature of the central metal atom play important roles in determining the ability of synthetic heme analogues to inhibit HO activity. 9, 10 SnMP differs from heme in that its central metal atom is tin, and the vinyl groups in the A and B pyrrole rings are reduced to ethyl groups. The resultant metal-porphyrin complex is extremely stable in vivo and the free metal is not released by any physiological process known.
The use of HO inhibitors such as SnMP to suppress the production of bilirubin in the immediate postnatal period seems inherently more logical than attempting to control elevated plasma bilirubin concentrations (PBC) in newborns by methods (i.e., PT and exchange transfusion) that attempt to dispose of excessive bilirubin only after the bile pigment has already been formed and entered the circulation.
The uncertainty of correctly identifying those infants who will require PT and those who will have to return to the hospital for treatment of hyperbilirubinemia because of early discharge supports the use of an inhibitor of bilirubin production, such as SnMP, as a pharmacologic means for pre-empting the development of severe hyperbilirubinemia in this large population of newborns.
We conducted a clinical trial at the Hospital Materno Infantil Ramon Sarda, Buenos Aires, Argentina. 11 To be included in the study, (1) infants had to be healthy and delivered between 38 and 41 weeks' gestational age after an uncomplicated pregnancy with a PBC between 256.5 M (15 mg/dl) and 307.8 M (18 mg/dl) 48 to 96 hours after birth, and (2) informed consent had been obtained from the parents. We excluded infants with: (1) any congenital anomalies; (2) evidence, or strong suspicion, of congenital infection; (3) neonatal complications (asphyxia, respiratory distress syndrome, metabolic and/or thermoregulation or hemodynamic alterations at birth); (4) birth weights that were less than the 10th or more than the 90th percentile for their gestational age; (5) maternal use of phenobarbital during the last month of pregnancy; (6) venous hematocrit 65%; (7) significant bruising or large cephalhematomas; or (8) hemolytic disease.
We found significant statistical differences between the study groups in the outcome variables ( Table 1) .
The administration of a single dose of SnMP entirely eliminated the need for PT; none of the 80 infants in the SnMP-treated group required supplemental PT, whereas 19 of 86 (22%) infants in the control group received PT. In addition, SnMP significantly reduced the maximum serum bilirubin level reached when compared with the control group. We explored the question of whether SnMP affected the distribution of maximum PBCs. It is clear that the distribution of maximum PBC was shifted to the left by SnMP treatment despite the fact that 19 of the 86 control infants required PT (p=0.0043, Mann-Whitney U test). The median time required between enrollment and closure was significantly reduced by SnMP administration from 120 hours in the control group to 86.5 hours in the SnMP-treated group (p<0.0001). In addition, the number of bilirubin measurements between enrollment and closure was reduced from 5 (median) to 3 by SnMP treatment (p<0.0001).
The study clearly demonstrated that a single dose of SnMP, administered to healthy full-term breast-fed newborns at a time when hyperbilirubinemia is becoming severe (15 to 18 mg/dl), could eliminate the need for PT and reduce both the number of bilirubin measurements and the length of time the infants are under clinical care for the problem of hyperbilirubinemia. Administration of SnMP was well tolerated and no side effects were observed.
These findings are consistent with the results of other previous studies 12, 13 that have demonstrated the efficacy of SnMP in controlling neonatal hyperbilirubinemia before plasma bilirubin reached levels potentially toxic to the central nervous system; and they extend the effectiveness of SnMP in controlling hyperbilirubinemia to a new and large population of newborns.
The uncertainties faced by clinicians regarding: (1) what is considered to be a threatening level of bilirubin in the circulation; (2) the inability to identify those infants who will reach a PBC at which PT is required, the Bhutani nomogram could be useful in this regard; and (3) the problem of infants lost from follow-up programs, lead us to propose the more general use of the therapeutic approach taken in this study that is designed to inhibit bilirubin production and thus pre-empt the development of severe hyperbilirubinemia. Thus, by interdicting the production of bilirubin for a short period immediately after birth, it would be possible to eliminate many of the uncertainties regarding bilirubin toxicity and treatment thresholds 14 that complicate the treatment of neonatal hyperbilirubinemia. This approach offers important advantages to both the newborns and to the clinicians involved in their care.
A related concern, difficult to quantitate but clearly understandable, is the emotional impact on the mother of having a sick infant. This entails frequent traveling to and form the hospital, additional blood sampling for bilirubin determinations, and separation from the infant if rehospitalization is required. This situation contrasts with the current practice of encouraging motherinfant interaction and bonding. Despite education from pediatricians and nursing staff, many mothers of healthy full-term infants consider jaundice a serious illness. 15 This is expressed by their concern and behavior and this population of jaundiced infants is considered to be vulnerable by their mothers. Based on the results described above by suppressing bilirubin production with SnMP, or a related HO inhibitor, we could eliminate the need for PT to treat progressive hyperbilirubinemia. 
